Kornimate/medical-research-clean huggingface dataset:
observational study of expected arf recovery

Conditions: Acute Respiratory Failure; Post Intensive Care Syndrome

Summary: this is an observational cohort study of the association between patient expectations for functional recovery and quality of life among acute respiratory failure survivors 6 months after hospital discharge.

this study will enroll adults who are diagnosed with acute respiratory failure during an icu admission and discharged from the icu alive. all participants will receive usual clinical care. participant expectations for functional recovery will be assessed before hospital discharge via a standardized questionnaire containing a visual analogue scale and questions about expected ability and importance of being able to perform activities of daily living and instrumental activities of daily living in 6 months. at 6 months, participants will be re-contacted by phone. study staff will administer questionnaires to assess whether patient expectations have been met. quality of life will be assessed using the whoqol-bref and the eq-5d-vas.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * respiratory failure managed in the icu, where respiratory failure is defined as ≥1 of the following: * mechanical ventilation via an endotracheal tube ≥ 24 hours or * non-invasive ventilation (cpap, bipap) ≥ 24 consecutive hours\* provided for acute respiratory failure (not for obstructive sleep apnea or other stable use) or * high flow nasal cannula with fio2 ≥ 0.5 and flow rate ≥ 30 lpm for ≥ 24 consecutive hours\* \*occasional rest periods of ≤ 1 hour each are not deducted from the calculation of consecutive hours. * expected by the clinical team to be discharged home alive exclusion criteria: * patient in icu \< 24 hours * mechanical ventilation at baseline or mechanical ventilation solely for airway protection or obstruction * residing in a medical institution at the time of hospital admission * homeless / prisoner / primary residence not in the usa / unable to communicate by telephone in english * more than mild dementia (either known diagnosis of moderate or worse dementia or iq-code \> 3.6; screening performed on patients \> 50 years old or with family reports of possible memory decline) * patient on hospice at or before time of enrollment * patients who, based solely on pre-existing medical problems (such as poorly controlled neoplasm or other end stage disease, including stage iv heart failure or severe burns), would not be expected to survive 6 months in the absence of the acute respiratory failure. * patients with neurological injury either receiving treatment for intracranial hypertension or who are not expected to return to consciousness. * pregnancy
the effect of message framing on blood donation-study 1

Conditions: Rh Negative Blood Donor

Summary: rh negative blood group is a rare blood group in china, as it only accounts for 0.3-0.4 percent of the han population. therefore, low inventory is often found in blood collection and supply agencies in many regions in china. on july 18, 2018 blood stockpile of o-negative and b-negative in guangzhou blood center reached the warning line, and we took measures for emergency recruitment. o-negative and b-negative blood donors whose last donation dates were between january 1, 2015 and december 31, 2017 were identified and randomly assigned to three groups. three different recruitment text messages were send to these groups respectively. at the same time, a-negative and ab-negative blood donors were marked as control group. we observed the re-donation rates among four groups within three months.


Eligibility criteria:
inclusion criteria: * rh- negative blood donors whose last donations were between january 1, 2015 and december 31, 2017. exclusion criteria: * donors with an obviously invalid phone number. donors whose serological results of the last donation were positive.
conventional spinal anaesthesia versus fractional spinal anaesthesia on hemodynamics

Conditions: Hip Fractures

Summary: compare the systemic haemodynamic response to fractional spinal anaesthesia versus conventional spinal anaesthesia , in a group of elderly and comorbid patients with hip fracture.

spinal anaesthesia affects sympathetic chain activity, leading to a reduction in vasomotor tone.it was found that the incidence of hypotension following single-shot spinal anaesthesia, has previously been described as being 28-69%. as a matter of fact, autonomic nervous system function plays a key role in the development of haemodynamic instability and intraoperative hypotension . haemodynamic stability should be considered as a primary intraoperative target, since several findings suggest avoiding systemic pressure drops . it was found that hypotension is primarily related to the overall dose injected ; however, several other variables, including the volume, the type of the anaesthetics injected, different adjuvant agents, and pre- and intraoperative factors, may impact the haemodynamic effect of the sa.

Eligibility criteria:
inclusion criteria: * patients with hip fractures. * patients age \>60 years old. * asa ≤ 3. exclusion criteria: * patients on anticoagulant medication. * planned for general anaesthesia . * patients had atrial fibrillation.

Keywords: fractional spinal
blood-brain barrier leakage in dementia. a dynamic contrast-enhanced mri study

Conditions: Alzheimer's Disease; Vascular Dementia

Summary: alzheimer's disease (ad) and vascular dementia (vad) are the most common forms of dementia. yet, the cause of these diseases is still unknown. a potentially important initiating factor is a disrupted blood-brain barrier. this can initiate cerebral microangiopathy, which has frequently been associated with vad. nevertheless, also in most ad patients a substantial increase of vascular damage has been observed. the present study investigates the correlation between blood-brain-barrier breakdown and cognitive decline in ad and vad. an innovative dynamic contrast-enhanced mri scan that has recently been developed and tested at our institute, will be used to measure blood-brain barrier permeability. objective: we will investigate the relationship between this permeability measure and (i) cognitive performance and (ii) the status of mri visible cerebrovascular pathology (i.e. white matter hyperintensities, lacunar infarctions, microbleeds) in the most common forms of dementia.


Eligibility criteria:
inclusion criteria: patients: * informed consent before participation in the study * age of 55 and older * diagnosed with ad, vad, mixed ad and vad, mild cognitive impairment, vascular cognitive impairment and subjective cognitive impairment * mmse ≥ 20 and patients are mentally competent (in general, individuals with an mmse ≥18 are considered mentally competent) healthy participants: * informed consent before participation in the study * age of 55 and older * no diagnosis of dementia, prodromal dementia, or mild cognitive impairment. * mmse ≥ 26 * no substantial memory complaints (according to participant) * average age, gender and education is similar to the patient groups. exclusion criteria: * contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, large body tattoos) * contraindications for contrast agent gadovist (renal failure) as determined by the estimated glomular filtration rate egfr \< 30 ml/min; or known allergy to gadovist. if participants have a low renal function as determined by \<30 gfr \<60, the pi will contact a radiologist (paul hofman). the radiologist will decide if this patient should be excluded. * major vascular disorders (e.g. stroke, heart disease) * psychiatric or neurological disorders: major depression (\< 12 months); history of schizophrenia; bipolar disorder; psychotic disorder nos or treatment for a psychotic disorder (\< 12 mnd); cognitive impairment due to alcohol abuse; epilepsy; parkinson's disease; ms; brain surgery; brain trauma; electroshock therapy; kidney dialysis; meniere's disease; and brain infections. * structural abnormalities of the brain * cognitive impairment due to alcohol/drug abuse or abuse of other substances. * absence of reliable informant (for patient groups)
gerd in children with cystic fibrosis

Conditions: GERD in Children; Cystic Fibrosis in Children

Summary: the purpose of this study is to use a survey to measure reflux symptoms in patients with cystic fibrosis who are on reflux treatment, and to monitor their symptoms after stopping the reflux treatment.


Eligibility criteria:
inclusion criteria: * children 6-17 years of age with a confirmed cf diagnosis by either a positive sweat test or 2 disease causing cftr mutations. * gerd medications documented at visit 1 * stable gerd medication dose for 3 months * pediatric gerd symptom assessment score \<80 * signed consent exclusion criteria: * declining to participate in the study or sign consent * unwillingness to stop gerd therapy * history of severe gerd per gastroenterology diagnosis and documentation * gsas score \>80
gene sequencing as a strategy for identifying genetic factors associated with serious adverse events after covid-19 vaccines in use in brazil

Conditions: Vaccine-induced Thrombotic Thrombocytopenia Syndrome; Guillain-Barre Syndrome; Acute Disseminated Encephalomyelitis; Transverse Myelitis

Summary: this protocol proposes to investigate genetic factors that may be involved in the pathogenesis of adverse events of interest with selected covid-19 vaccines: vaccine-induced immune thrombotic thrombocytopenia, and neurological adverse events, such as guillain-barré syndrome, acute disseminated encephalomyelitis and transverse myelitis, with the intention of identifying useful biomarkers in identifying people at higher risk, thus reducing the occurrence of these serious adverse events (sae).

participants higher than 5 years old with no maximum age limit and both sexes, who had a serious adverse event after vaccination against covid-19, such as guillain-barré syndrome, vaccine-induced immune thrombotic thrombocytopenia, transverse myelitis and acute disseminated encephalomyelitis. parents, siblings and/or sons of cases with sae will have biological samples collected and stored; depending on the result of the study, they may have their samples analyzed later.

Eligibility criteria:
inclusion criteria: * sign the icf by the subject or the subject's legally acceptable representative; * sign the icf by the participant's family member; * proven vaccination with one of the vaccines for covid-19 available by the pni, containing information on the date of application, type (manufacturer) of vaccine received and batch (desirable); * meet the minimum criteria for a level of certainty 3, 2 or 1 in brighton collaboration for vaccine-induced immune thrombotic thrombocytopenia as described in 3.2.1.1 or, * meet the minimum criteria for a level of certainty 3, 2 or 1 in brighton collaboration for guillain-barré syndrome as described in 3.2.1.3 or, * meet the minimum criteria for a level of certainty 3, 2 or 1 in brighton collaboration for acute disseminated encephalomyelitis as described in 3.2.1.4 or, * meet the minimum criteria for a level of certainty 3, 2 or 1 in brighton collaboration for transverse myelitis as described in 3.2.1.5 or, * be classified in the causality categories adopted by the pni/ms, namely: a1, b1 or b2. exclusion criteria: * reports in which it is not possible to retrieve the clinical/laboratory data necessary for evaluation, due to inadequate filling of the notification or unavailability of data; * cases of death in which there are no samples available and/or suitable for carrying out the analyzes defined in the protocol; * cases in which another diagnosis is made for the adverse event of interest, being discarded as a sae; * cases classified in causality categories (pni/ms) as a2, a3, a4, c or d; * refusal to sign the informed consent form;

Keywords: vaccine-induced thrombotic thrombocytopenia guillain-barre syndrome acute disseminated encephalomyelitis transverse myelitis covid-19 vaccine seriuos adverse events
efficacy and safety of ibi310 combined with sintilimab in patients with advanced hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma

Summary: an open-label, single-arm, ib study of the efficacy and safety of ibi310 combined with sintilimab in patients with advanced hepatocellular carcinoma

in this study, approximately 18 to 47 patients who have previously received sorafenib, lenvatinib, or oxaliplatin-containing chemotherapy . after determining the dose of ibi310, the study will enter the expansion phase

Eligibility criteria:
inclusion criteria： 1. locally advanced or metastatic hepatocellular carcinoma, confirmed by histology/cytology. 2. disease progression after surgery and / or local treatment. 3. previous standard systemic treatments for advanced hepatocellular carcinoma have failed or developed intolerable toxicity. exclusion criteria： 1. histology contains fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma and other components. 2. have a history of hepatic encephalopathy, or have a history of liver transplantation. 3. diffuse liver cancer.
different music types in reducing dental anxiety in young people

Conditions: Dental Anxiety

Summary: anxiety is an important issue in dental care for adults, children and adolescents. dental anxiety affects 10-20% of adults and 43% of children and adolescents. dental anxiety often leads to avoiding dental treatment; this can cause serious deterioration of oral and dental health. such deterioration can significantly increase dental care costs. therefore, reducing anxiety is important both in terms of patient, physician and cost. music intervention is a psychological therapy that has many advantages when used in outpatient treatment, including cost-effectiveness, lack of negative physical effects, rapid effect, lack of safety in terms of non-use and lack of concern for recovery. some types of studies suggested but not tested against each other include classical music, soft rock, calming music, pop, easy listening music, and music of choice. with the contradictory results of various studies, the fact that the distraction of music and its distraction on the reduction of tooth anxiety is not common shows that a more structured study is needed. the lack of precise data on the effects of different music types on anxiety has led to this study.


Eligibility criteria:
inclusion criteria: * 3. molar tooth extraction, * 18-30 years old, * symptomatic exclusion criteria: * who does not agree to participate in the study, * under 18 years, over 30 years, * patients with impaired hearing (ie, not suitable for musical intervention), * arrhythmia * patients with physical condition iii or higher (american society of anesthesiologists)
copper cu-64 tp3805 pet/ct in imaging patients with urothelial cancer undergoing surgery or biopsy

Conditions: Bladder Urothelial Carcinoma; Urothelial Carcinoma

Summary: this pilot clinical trial studies how well copper cu-64 tp3805 positron emission tomography (pet)/computed tomography (ct) works in imaging patients with urothelial cancer undergoing surgery or biopsy. radioactive tracers, such as copper cu-64 tp3805, may bind to tumor cells. pet/ct imaging performed with copper cu-64 tp3805 may be a better way to detect urothelial cancer.

primary objectives: i. to determine if copper cu-64 tp3805 (cu-64-tp3805) shall image urothelial carcinoma (uc) as confirmed by postsurgical or biopsy histology. secondary objectives: i. to determine blood clearance of cu-64-tp3805. ii. to determine in vivo stability of cu-64-tp3805. tertiary: i. to determine if cu-64-tp3805 is bound to malignant cells and if it is internalized.

Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form * willing to comply with all study procedures and be available for the duration of the study * must have diagnosis of urothelial cancer * scheduled for extirpative surgery or biopsy of suspected metastatic lesion * women of reproductive potential must have a urine pregnancy test day of injection * men of reproductive potential must use condoms exclusion criteria: * pregnancy or lactation * known allergic reactions to components of the study product(s) * treatment with another investigational drug or other intervention with 24 hours of injection * must not have had an injection of a radioisotope 24 hours prior to exam
stair for trauma and emotion dysregulation

Conditions: Posttraumatic Stress Disorder; Borderline Personality Disorder; Emotion Regulation

Summary: this study will examine the impact of skills training in affective and interpersonal regulation (stair) group, using self-report measures, on posttraumatic stress disorder (ptsd), emotional dysregulation, borderline personality disorder symptoms, global psychopathology, and access to quality mental health care. aims include assessing the feasibility of stair, reducing patients' trauma and emotion dysregulation symptoms, examining whether stair may be used as an alternative to dbt for patients on the dbt, and improving patient satisfaction and clinic efficiency


Eligibility criteria:
inclusion criteria: * be 18 years or older. * have a dsm-5 diagnosis and/or symptoms for which dbt is an indicated treatment * meet dsm-5 criteria for a diagnosis of posttraumatic stress disorder (ptsd) * meet criteria at a subclinical level for bpd (a minimum of three symptoms) * must be able to make group commitments for attendance, safety, and sobriety during group exclusion criteria: * if currently receiving individual therapy that follows the dbt protocol or is an evidence-based trauma-focused therapy * if the stair therapy group is determined to be clinically contraindicated
a study of once monthly subcutaneous mircera in dialysis patients with chronic renal anemia

Conditions: Anemia

Summary: this single arm study will assess the efficacy, safety and tolerability of once monthly administration of subcutaneous mircera for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia. patients will receive subcutaneous mircera at a starting dose of 120, 200 or 360 micrograms every 4 weeks, calculated from the last weekly dose of epoetin or darbepoetin alfa previously administered. subsequent doses will be adjusted to maintain hemoglobin levels within the target range. treatment duration is 56 weeks, and the target sample size is 200 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * chronic renal anemia; * regular long-term hemodialysis or peritoneal dialysis, with same mode of dialysis for \>=3 months; * continuous iv maintenance epoetin alfa therapy with same dosing interval during previous 2 months. exclusion criteria: * transfusion of red blood cells during previous 2 months; * poorly controlled hypertension; * significant acute or chronic bleeding; * active malignant disease (except non-melanoma skin cancer).
dysport® injection in the treatment of chronic lateral epicondylitis

Conditions: Tennis Elbow

Summary: the purpose of this study is to determine whether a single injection of dysport with a new protocol at forearm is effective in the management of chronic lateral epicondylitis.

some studies valued the effectiveness of botulinum toxin. there is a great amount of controversy on the amount of botulinum toxin injected and the location of the injection. the purpose of the study is to compare the effectiveness of botulinum toxin injection with placebo at a new injection site at the forearm in the treatment of chronic tennis elbow unrelieved by corticosteroid injection and physiotherapy. it is a double blind randomized controlled trial.

Eligibility criteria:
inclusion criteria: * pain: pain will be assessed as the physician touches lateral epicondyle or passively flexing the patient's wrist and while the patient extends his/her wrist or 3rd finger against resistance. individuals who fulfill two or more of above will be considered to have lateral epicondylitis. * symptom duration: should be at least 6 months. * previous trial of complete course of physiotherapy and corticosteroid injection. exclusion criteria: * rheumatoid arthritis * generalized polyarthritis * local elbow arthritis * simultaneous medial epicondylalgia * bilateral lateral epicondylitis * neurologic deficits (abnormal light touch sensation, deep tendon reflexes abnormality, radicular pain, radial nerve entrapment, signs of nerve root compression, decreased muscle force, multiple sclerosis, seizures) * the use of corticosteroid in last 30 days * simultaneous use of drugs other than acetaminophen or physical therapy in the course of study * pregnancy * breast-feeding * previous hand surgery * having a hobby or job that needs finger extension

Keywords: tennis elbow botulinum toxin
cardiac metabolic modulator treatment for improvement of diastolic function in patients with coronary heart disease

Conditions: Coronary Heart Disease; Diastolic Dysfunction

Summary: based on accumulating evidence showing that impaired cardiac energetic metabolism plays important role in the mechanism of cardiac diastolic dysfunction,the study is designed to evaluate whether metabolic modulator treatment with trimetazidine could have beneficial effects on patients with coronary heart disease(chd) and ventricular diastolic dysfunction.this study is a prospective,randomised,open-label trial to assess the efficacy of trimetazidine treatment in improving diastolic function in chd patients with diastolic dysfunction.

the primary objective of this trial is to determine whether the 24-week trimetazidine therapy, as an adjunct to routine treatment for chd, would improve diastolic function in patients with ischemic heart disease compared to the routine treatment.

Eligibility criteria:
inclusion criteria: * aged between 50 and 79 years,male or female (without pregnancy). * diagnosed chd by coronary angiography,with stenoses in main bifurcations less than 70% after pci treatment. * left ventricular ejection fraction(lvef) more than 50% assessed by ultracardiography. * characteristics of diastolic dysfunction by ultracardiography (more than 2 criteria as following):(1)average e/e'\>14,(2)septal e' velocity \ 2.8m/s,(4)left atrium (la) volume index \>34ml/m2. * not yet being treated by trimetazidine. * provided informed consent. exclusion criteria: * acute heart failure or acute exacerbation of chronic heart failure. * lvef less than 50% at admission or in the past. * history of malignant tumor or life expectancy under 12 months. * acute myocardial infarction or unstable angina pectoris within 3 months. * scheduled coronary artery bypass grafting therapy within 6 months. * diagnosed or considered valvular heart disease, hypertrophic cardiomyopathy,restrictive cardiomyopathy or pericardium diseases. * significant hepatic impairment (serum glutamate-pyruvate transaminase more than 3 times normal upper limit) or severe renal dysfunction (egfr≤30 ml/min/1.73m2). * known or considered parkinson's disease. * known hypersensitivity or intolerance to trimetazidine. * pregnancy and lactation period. * any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol. * participation in another clinical trial within the past 30 days.